Skip to main content

Evaluating the Effects of a 14-Day Oral Chemotherapy Dispensing Protocol on Adherence, Toxicity, and Cost

Audiocasts - Original Research
Shardae Young, PharmD, BCPS
Clinical Pharmacy Specialist
Oncology
at VA Texas Valley Coastal Bend Health Care System
Harlingen,TX.
Shardae Young, PharmD, BCPS, Clinical Pharmacy Specialist, Oncology, VA Texas Valley Coastal Bend Health Care System, Harlingen,TX, discusses the clinical significance of her study, “Evaluating the Effects of a 14-Day Oral Chemotherapy Dispensing Protocol on Adherence, Toxicity, and Cost.”
Related Items
A Standardized Pharmacist-Guided Emesis Workflow: Implementation of Clinical Practice Guideline–Consistent Antiemetic Therapy in Children Undergoing Hematopoietic Stem Cell Transplantation
JHOP - October 2026 Vol 16, No 5 published on May 18, 2026 in Original Research, Adverse Events, Transplant, Drug Resistance, Oncology Pharmacy Programs/Protocols
CNS Prophylaxis in Patients With Diffuse Large B-Cell Lymphoma
JHOP - October 2026 Vol 16, No 5 published on May 12, 2026 in Original Research, Lymphoma, Methotrexate, Chemotherapy
Feasibility of Supplemental Materials Alongside Pharmacist-Led Chemotherapy Education: A Prospective Pilot Study
JHOP - August 2026 Vol 16, No 4 published on April 29, 2026 in Original Research, Chemotherapy, Oncology Pharmacy Programs/Protocols, Practical Issues in Pharmacy Management, Technology
Pharmacist-Led Management of Concomitant Medications in Oncology Trials: A Retrospective Analysis of Screening and Enrollment Outcomes
JHOP - February 2027 Vol 17, No 1 published on April 20, 2026 in Original Research, Clinical Trials, Drug–Drug Interaction
Impact of Pharmacist-Driven Oral Chemotherapy Treatment Plan Implementation on Monitoring and Supportive Care Interventions During CDK4/6 Inhibitor Therapy for Patients With Breast Cancer
JHOP - December 2026 Vol 16, No 6 published on April 20, 2026 in Original Research, Chemotherapy, Oncology Pharmacy Programs/Protocols, Supportive Care, Breast Cancer
Arthralgia Rates and Treatment Among Patients Receiving Bevacizumab-awwb Versus Bevacizumab
JHOP - August 2026 Vol 16, No 4 published on April 3, 2026 in Original Research, Adverse Events, Biosimilars
Glucarpi-CAP: A Retrospective Case Series of 1000-Unit Glucarpidase Dosing for Methotrexate Rescue
JHOP - December 2026 Vol 16, No 6 published on March 31, 2026 in Original Research, Methotrexate, Case Reports
Expanding Bispecific T-Cell Engager Therapy for Multiple Myeloma to Community Settings: A Single-Institution Experience
JHOP - December 2026 Vol 16, No 6 published on March 26, 2026 in Original Research, Bispecific Antibodies, Multiple Myeloma
Characterization of A Dose-Dense Doxorubicin and Cyclophosphamide Regimen for Triple-Negative Breast Cancer Within the KEYNOTE-522 Trial
JHOP - December 2026 Vol 16, No 6 published on March 25, 2026 in Original Research, Immunotherapy, Chemotherapy, Breast Cancer
Characterizing Lenalidomide Dose Modifications Among Black and Non-Black Patients Receiving Induction Therapy for Newly Diagnosed Multiple Myeloma
JHOP - October 2026 Vol 16, No 5 published on March 23, 2026 in Original Research, Adverse Events, Disparities in Oncology Care, Dose Escalation/Reduction, Immunotherapy, Multiple Myeloma